Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Practice Point
  • Published:

Does paricalcitol reduce proteinuria in patients with chronic kidney disease?

Nature Clinical Practice Nephrology volume 2, pages 352–353 (2006)Cite this article

boxed-textAgarwal R et al. (2005) Antiproteinuric effect of oral paricalcitol in chronic kidney disease. Kidney Int 68: 2823–2828

Background

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Teng M et al. (2005) Activated injectable vitamin D and hemodialysis survival: a historical cohort study. J Am Soc Nephrol 16: 1115–1125

    Article  CAS  Google Scholar 

  2. Shoji T et al. (2004) Lower risk for cardiovascular mortality in oral 1α-hydroxy vitamin D3 users in a haemodialysis population. Nephrol Dial Transplant 19: 179–184

    Article  CAS  Google Scholar 

  3. Levin A and Li YC (2005) Vitamin D and its analogues: do they protect against cardiovascular disease in patients with kidney disease? Kidney Int 68: 1973–1981

    Article  Google Scholar 

  4. National Kidney Foundation (2003) K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Am J Kidney Dis 42: S1–S201

Download references

Acknowledgements

The synopsis was written by Chloë Harman, Associate Editor, Nature Clinical Practice.

Author information

Authors and Affiliations

  1. Chair of the Department of Metabolism, Professor of Medicine, Endocrinology and Molecular Medicine,

    Yoshiki Nishizawa & Tetsuo Shoji

  2. Dean of Osaka City University Graduate School of Medicine,

    Yoshiki Nishizawa & Tetsuo Shoji

  3. Department of Metabolism, Endocrinology and Molecular Medicine at Osaka City University Graduate School of Medicine, Osaka, Japan

    Yoshiki Nishizawa & Tetsuo Shoji

Authors
  1. Yoshiki Nishizawa
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Tetsuo Shoji
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Yoshiki Nishizawa.

Ethics declarations

Competing interests

The authors declare no competing financial interests.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Nishizawa, Y., Shoji, T. Does paricalcitol reduce proteinuria in patients with chronic kidney disease?. Nat Rev Nephrol 2, 352–353 (2006). https://doi.org/10.1038/ncpneph0206

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1038/ncpneph0206

This article is cited by

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing